NM8074, an investigational antibody therapy for paroxysmal nocturnal hemoglobinuria (PNH), will now be called ruxoprubart, its developer NovelMed has announced. The name change came after the USAN, or United States Adopted Names Council, selected ruxoprubart as the unique generic, or nonproprietary, name for the therapy candidate. According to…
News
Danicopan has been approved in Japan as a first-in-class, add-on therapy for people with paroxysmal nocturnal hemoglobinuria (PNH) who have an insufficient response to treatment with C5 inhibitors. Its developer Alexion, AstraZeneca Rare Disease will be marketing it under the brand name Voydeya, the company announced in a…
Danicopan, an experimental oral medication, continued to help control anemia when taken for up to 48 weeks by adults with paroxysmal nocturnal hemoglobinuria (PNH) who experience a breakdown of red blood cells outside of blood vessels — called extravascular hemolysis — despite being on a C5 inhibitor. That’s according…
This year, PNH News brought up-to-date coverage of the latest scientific and clinical research developments in paroxysmal nocturnal hemoglobinuria (PNH). Here are the 10 most-read news stories of 2023, along with a brief description of what made them interesting to our readers. We look forward to continuing to…
Long-term treatment with Soliris (eculizumab) safely and effectively reduced the severity of paroxysmal nocturnal hemoglobinuria (PNH) in Korean adults with high disease activity, according to a real-world study. Soliris was found to ease PNH symptoms, including fatigue, anemia — low levels of hemoglobin, the protein in red…
Taking Novartis’ Fabhalta (iptacopan) as a monotherapy — meaning as a sole treatment — twice daily for almost one year continued to sustain hemoglobin at near-normal levels, generally without the need for blood transfusions, in adults with paroxysmal nocturnal hemoglobinuria (PNH). These new data come from an open-label…
Treatment with Empaveli (pegcetacoplan) — a C3 protein blocker — effectively improved disease control and health-related quality of life, while reducing fatigue in people with paroxysmal nocturnal hemoglobinuria (PNH) in the U.S. and Europe, a real-world study reported. Study findings also showed higher physician and patient satisfaction with…
The U.S. Food and Drug Administration (FDA) has approved iptacopan for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). It will be sold under the brand name Fabhalta. As the first oral monotherapy approved for the rare condition in the U.S., Fabhalta is expected to become available…
Add-on danicopan treatment led to better control of anemia among paroxysmal nocturnal hemoglobinuria (PNH) patients experiencing residual red blood cell destruction, or hemolysis, while on Soliris (eculizumab) or Ultomiris (ravulizumab), according to data from a Phase 3 clinical trial. The addition of the investigational oral therapy to…
A rare case of portal vein thrombosis (PVT) — where a clot blocks blood flow in the portal vein, a major liver blood vessel — in a 49-year-old woman with paroxysmal nocturnal hemoglobinuria (PNH) was detailed in a case report. Transjugular intrahepatic portosystemic shunt (TIPS), a surgical procedure that…
Recent Posts
- Improving quality of life is key to living fully with PNH
- New PNH case report shows anemia improved after treatment change
- PNH treatment ruxoprubart shows promise in Phase 2 trial
- Real-world study: Ultomiris is preferred treatment option for PNH
- New questionnaire assessing fatigue ‘reliable and valid’ for adults with PNH